Shanghai Junshi Biosciences Co.,Ltd. (688180.SH): JT118 Injection Clinical Trial for Monkeypox Virus Prevention Receives Approval

Stock News

Sep 02

Shanghai Junshi Biosciences Co.,Ltd. (688180.SH) announced that its controlling subsidiary, Shanghai Juntuo Biomedical Technology Co., Ltd., has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for JT118 injection has been approved, with the National Medical Products Administration agreeing to commence clinical trials for the prevention of monkeypox virus infection.

JT118 is a "2-in-1" recombinant protein vaccine composed of tandem fusion of monkeypox virus antigens A35 (extracellular enveloped virus antigen) and M1 (intracellular mature virus antigen), primarily intended for preventing monkeypox virus infection.

Monkeypox is a zoonotic viral disease caused by monkeypox virus infection. The monkeypox virus is classified under the genus Orthopoxvirus of the Poxviridae family. During poxvirus replication, two morphologically different viral particles are produced: extracellular enveloped viruses and intracellular mature viruses, both of which are infectious.

JT118 not only preserves the epitope structures of both natural antigens A35 and M1, but also significantly increases the molecular weight through multi-antigen fusion, making it more conducive to immune stimulation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1120214027"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120214027\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120214027?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 19:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120214027","market":"hk","top_or_hot":-1,"title":"Shanghai Junshi Biosciences Co.,Ltd. (688180.SH): JT118 Injection Clinical Trial for Monkeypox Virus Prevention Receives Approval","media":"Stock News","content":"<p>Shanghai Junshi Biosciences Co.,Ltd. (688180.SH) announced that its controlling subsidiary, Shanghai Juntuo Biomedical Technology Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration. The clinical trial application for JT118 injection has been approved, with the National Medical Products Administration agreeing to commence clinical trials for the prevention of monkeypox virus infection.</p>\n<p>JT118 is a \"2-in-1\" recombinant protein vaccine composed of tandem fusion of monkeypox virus antigens A35 (extracellular enveloped virus antigen) and M1 (intracellular mature virus antigen), primarily intended for preventing monkeypox virus infection.</p>\n<p>Monkeypox is a zoonotic viral disease caused by monkeypox virus infection. The monkeypox virus is classified under the genus Orthopoxvirus of the Poxviridae family. During poxvirus replication, two morphologically different viral particles are produced: extracellular enveloped viruses and intracellular mature viruses, both of which are infectious.</p>\n<p>JT118 not only preserves the epitope structures of both natural antigens A35 and M1, but also significantly increases the molecular weight through multi-antigen fusion, making it more conducive to immune stimulation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Junshi Biosciences Co.,Ltd. (688180.SH): JT118 Injection Clinical Trial for Monkeypox Virus Prevention Receives Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Junshi Biosciences Co.,Ltd. (688180.SH): JT118 Injection Clinical Trial for Monkeypox Virus Prevention Receives Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-02 19:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Junshi Biosciences Co.,Ltd. (688180.SH) announced that its controlling subsidiary, Shanghai Juntuo Biomedical Technology Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration. The clinical trial application for JT118 injection has been approved, with the National Medical Products Administration agreeing to commence clinical trials for the prevention of monkeypox virus infection.</p>\n<p>JT118 is a \"2-in-1\" recombinant protein vaccine composed of tandem fusion of monkeypox virus antigens A35 (extracellular enveloped virus antigen) and M1 (intracellular mature virus antigen), primarily intended for preventing monkeypox virus infection.</p>\n<p>Monkeypox is a zoonotic viral disease caused by monkeypox virus infection. The monkeypox virus is classified under the genus Orthopoxvirus of the Poxviridae family. During poxvirus replication, two morphologically different viral particles are produced: extracellular enveloped viruses and intracellular mature viruses, both of which are infectious.</p>\n<p>JT118 not only preserves the epitope structures of both natural antigens A35 and M1, but also significantly increases the molecular weight through multi-antigen fusion, making it more conducive to immune stimulation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1120214027","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120214027","pubTimestamp":1756813007,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Junshi Biosciences Co.,Ltd. (688180.SH) announced that its controlling subsidiary, Shanghai Juntuo Biomedical Technology Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\"...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","01877":"君实生物","BK1583":"高瓴概念","BK0239":"医药制造","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"上海君实生物科技有限公司。(688180.SH)：JT118注射液预防猴痘病毒临床试验获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1},"content_text":"Shanghai Junshi Biosciences Co.,Ltd. (688180.SH) announced that its controlling subsidiary, Shanghai Juntuo Biomedical Technology Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration. The clinical trial application for JT118 injection has been approved, with the National Medical Products Administration agreeing to commence clinical trials for the prevention of monkeypox virus infection.\nJT118 is a \"2-in-1\" recombinant protein vaccine composed of tandem fusion of monkeypox virus antigens A35 (extracellular enveloped virus antigen) and M1 (intracellular mature virus antigen), primarily intended for preventing monkeypox virus infection.\nMonkeypox is a zoonotic viral disease caused by monkeypox virus infection. The monkeypox virus is classified under the genus Orthopoxvirus of the Poxviridae family. During poxvirus replication, two morphologically different viral particles are produced: extracellular enveloped viruses and intracellular mature viruses, both of which are infectious.\nJT118 not only preserves the epitope structures of both natural antigens A35 and M1, but also significantly increases the molecular weight through multi-antigen fusion, making it more conducive to immune stimulation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}